This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

Currently, Vertex Pharmaceuticals is a Zacks Rank #3 (Hold ... At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Dunhill Financial LLC grew its stake in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 ...

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...